CTI BioPharma Corp. (CTIC)

Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Last trade price
Market Cap 1.20B
Revenue (ttm) 75.77M
Net Income (ttm) -69.24M
Shares Out 131.88M
EPS (ttm) -0.56
PE Ratio -16.23
Forward PE -47.81
Dividend n/a
Ex-Dividend Date n/a
Volume 11,420,980
Open 9.10
Previous Close 9.09
Day's Range 9.09 - 9.10
52-Week Range 4.01 - 9.10
Beta 0.83
Analysts Buy
Price Target 9.80 (+7.81%)
Earnings Date Aug 7, 2023

About CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 21, 1997
Employees 127
Stock Exchange NASDAQ
Ticker Symbol CTIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CTIC stock is "Buy." The 12-month stock price forecast is $9.8, which is an increase of 7.81% from the latest price.

Price Target
$9.8
(7.81% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sobi completes acquisition of CTI BioPharma Corp.

STOCKHOLM , June 26, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the acquisition of CTI by ...

9 months ago - PRNewsWire

Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO...

9 months ago - PRNewsWire

CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CTI BioPharma Co...

10 months ago - Business Wire

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies f...

10 months ago - PRNewsWire

Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO...

11 months ago - PRNewsWire

Swedish drugmaker SOBI to acquire Seattle biotech giant CTI BioPharma for $1.7B

CTI BioPharma, a Seattle-based publicly traded biotech company developing therapies for blood-related cancers, is set to be acquired in a deal with Swedish biotech giant Sobi.

11 months ago - GeekWire

Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi

MILWAUKEE , May 10, 2023 /PRNewswire/ -- Ademi LLP is investigating CTI BioPharma (Nasdaq: CTIC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sobi.  Clic...

11 months ago - PRNewsWire

CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CTI BioPharma Corp. (NASDAQ: CTIC) to Swedish Orphan Biovitrum AB for $9.10 per share is ...

11 months ago - Business Wire

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.

11 months ago - Barrons

CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings

CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. ...

Other symbols: RIVNUPST
11 months ago - Market Watch

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based dr...

11 months ago - Market Watch

Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTIO...

11 months ago - PRNewsWire

Sobi to Acquire CTI BioPharma

Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commer...

11 months ago - PRNewsWire

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-...

11 months ago - PRNewsWire

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-...

11 months ago - PRNewsWire

CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

– Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion – SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commerci...

11 months ago - PRNewsWire

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies ...

1 year ago - PRNewsWire

CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results

– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 an...

1 year ago - PRNewsWire

CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference

SEATTLE , March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo...

1 year ago - PRNewsWire

CTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023

SEATTLE , Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo...

1 year ago - PRNewsWire

CTI BioPharma to Participate in Upcoming Investor Conferences in February 2023

SEATTLE , Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2...

1 year ago - PRNewsWire

CTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SEATTLE , Jan. 5, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San ...

1 year ago - PRNewsWire

CTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition

SEATTLE , Dec. 11, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American ...

1 year ago - PRNewsWire

CTI BioPharma to Present at the JMP Securities Hematology and Oncology Summit

SEATTLE , Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3...

1 year ago - PRNewsWire

CTI BioPharma to Present at Upcoming November Conferences

SEATTLE , Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London....

1 year ago - PRNewsWire